Please try another search
China Jo-Jo Drugstores, Inc. reported earnings results for the half year ended September 30, 2023. For the half year, the company reported sales was USD 78.57 million compared to USD 72.72 million a year ago. Net loss was USD 0.924247 million compared to USD 0.594781 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 2.62 a year ago. Diluted loss per share from continuing operations was USD 0.77 compared to USD 2.62 a year ago.
Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
---|---|---|---|---|
Total Revenue | 39.29 | 39.29 | 38.04 | 38.04 |
Gross Profit | 7.97 | 7.97 | 8.68 | 8.68 |
Operating Income | 0.128 | 0.128 | -9.84 | -9.84 |
Net Income | -0.462 | -0.462 | -10.27 | -10.27 |
Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
---|---|---|---|---|
Total Assets | 94.77 | 94.77 | 90.97 | 90.97 |
Total Liabilities | 77.23 | 77.23 | 74.3 | 74.3 |
Total Equity | 17.54 | 17.54 | 16.67 | 16.67 |
Period Ending: | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 0.361 | 0.361 | -2.17 | -2.17 |
Cash From Investing Activities | -0.663 | -0.663 | -0.116 | -0.116 |
Cash From Financing Activities | 0.164 | 0.164 | 2.67 | 2.67 |
Net Change in Cash | -0.985 | -0.985 | 1.06 | 1.06 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review